Medication adherence and fracture risk among patients on bisphosphonate therapy in a large United States health plan

Bone

Volumn 50, Issue 4, 2012, Pages 870-875

  Wade, Sally W ^a   Curtis, Jeffrey R ^b   Yu, Jingbo ^c,g   White, Jeffrey ^d   Stolshek, Bradley S ^e   Merinar, Claire ^e   Balasubramanian, Akhila ^e   Kallich, Joel D ^e   Adams, John L ^f   Viswanathan, Hema N ^e  

^a Wade Outcomes Research and Consulting   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c HEALTHCORE INC   (United States)

^d Wellpoint Inc   (United States)

^e AMGEN INC   (United States)

^f RAND CORPORATION   (United States)

^g NONE   (United States)

Author keywords

Adherence; Fracture; Observational; Osteoporosis; Persistence

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; IBANDRONIC ACID; PARATHYROID HORMONE[1-34]; RALOXIFENE; RISEDRONIC ACID; ZOLEDRONIC ACID;

ADULT; AGED; ARTICLE; CLINICAL EFFECTIVENESS; COMORBIDITY; CONTROLLED STUDY; DEMOGRAPHY; DRUG EFFICACY; DRUG USE; FEMALE; FEMUR FRACTURE; FOLLOW UP; FOREARM FRACTURE; FRACTURE; HEALTH CARE PLANNING; HEALTH INSURANCE; HIP FRACTURE; HUMAN; HUMERUS FRACTURE; MAJOR CLINICAL STUDY; MALE; OSTEOPOROSIS; PATIENT COMPLIANCE; PELVIS FRACTURE; RADIUS FRACTURE; RETROSPECTIVE STUDY; RISK ASSESSMENT; ULNA FRACTURE; UNITED STATES; VERTEBRA FRACTURE;

EID: 84862776756     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2011.12.021     Document Type: Article

References (20)

1. Cramer J.A., Roy A., Burrell A., Fairchild C.J., Fuldeore M.J., Ollendorf D.A., et al. Medication compliance and persistence: terminology and definitions. Value Health 2008, 11:44-47.
2. Brookhart M.A., Avorn J., Katz J.N., Finkelstein J.S., Arnold M., Polinski J.M., et al. Gaps in treatment among users of osteoporosis medications: the dynamics of noncompliance. Am J Med 2007, 120:251-256.
3. Cramer J.A., Amonkar M.M., Hebborn A., Altman R. Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin 2005, 21:1453-1460.
4. Gold D.T., Silverman S. Review of adherence to medications for the treatment of osteoporosis. Curr Osteoporos Rep 2006, 4:21-27.
5. Siris E.S., Selby P.L., Saag K.G., Borgstrom F., Herings R.M., Silverman S.L. Impact of osteoporosis treatment adherence on fracture rates in North America and Europe. Am J Med 2009, 122:S3-S13.
6. Imaz I., Zegarra P., Gonzalez-Enriquez J., Rubio B., Alcazar R., Amate J.M. Poor bisphosphonate adherence for treatment of osteoporosis increases fracture risk: systematic review and meta-analysis. Osteoporos Int 2010, 21:1943-1951.
7. Curtis J.R., Mudano A.S., Solomon D.H., Xi J., Melton M.E., Saag K.G. Identification and validation of vertebral compression fractures using administrative claims data. Med Care 2009, 47:69-72.
8. Warriner A.H., Patkar N.M., Curtis J.R., Delzell E., Gary L., Kilgore M., et al. Which fractures are most attributable to osteoporosis?. J Clin Epidemiol 2011, 64:46-53.
9. Kothawala P., Badamgarav E., Ryu S., Miller R.M., Halbert R.J. Systematic review and meta-analysis of real-world adherence to drug therapy for osteoporosis. Mayo Clin Proc 2007, 82:1493-1501.
10. Cadarette S.M., Burden A.M. Measuring and improving adherence to osteoporosis pharmacotherapy. Curr Opin Rheumatol 2010, 22:397-403.
11. Curtis J.R., Xi J., Westfall A.O., Cheng H., Lyles K., Saag K.G., et al. Improving the prediction of medication compliance: the example of bisphosphonates for osteoporosis. Med Care 2009, 47:334-341.
12. Mabotuwana T., Warren J., Harrison J., Kenealy T. What can primary care prescribing data tell us about individual adherence to long-term medication?-Comparison to pharmacy dispensing data. Pharmacoepidemiol Drug Saf 2009, 18:956-964.
13. Yu A.P., Yu Y.F., Nichol M.B., Gwadry-Sridhar F. Delay in filling the initial prescription for a statin: a potential early indicator of medication nonpersistence. Clin Ther 2008, 30:761-774. discussion 716.
14. Hansen R.A., Dusetzina S.B., Dominik R.C., Gaynes B.N. Prescription refill records as a screening tool to identify antidepressant non-adherence. Pharmacoepidemiol Drug Saf 2010, 19:33-37.
15. Zambon A., Baio G., Mazzaglia G., Merlino L., Corrao G. Discontinuity and failures of therapy with bisphosphonates: joint assessment of predictors with multi-state models. Pharmacoepidemiol Drug Saf 2008, 17:260-269.
16. Gold D.T., Trinh H., Safi W. Weekly versus monthly drug regimens: 1-year compliance and persistence with bisphosphonate therapy. Curr Med Res Opin 2009, 25:1831-1839.
17. Lekkerkerker F., Kanis J.A., Alsayed N., Bouvenot G., Burlet N., Cahall D., et al. Adherence to treatment of osteoporosis: a need for study. Osteoporos Int 2007, 18:1311-1317.
18. Gleeson T., Iversen M.D., Avorn J., Brookhart A.M., Katz J.N., Losina E., et al. Interventions to improve adherence and persistence with osteoporosis medications: a systematic literature review. Osteoporos Int 2009, 20:2127-2134.
19. Warriner A.H., Curtis J.R. Adherence to osteoporosis treatments: room for improvement. Curr Opin Rheumatol 2009, 21:356-362.
20. Peterson A.M., Nau D.P., Cramer J.A., Benner J., Gwadry-Sridhar F., Nichol M. A checklist for medication compliance and persistence studies using retrospective databases. Value Health 2007, 10:3-12.